275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2020. Parexel International Corporation.
275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2020. Parexel International Corporation.
Learn how Parexel's partnership with Microsoft is working to accelerate R&D.
Chief Commercial & Strategy Officer, Peyton Howell, on how keeping patients at the heart of our efforts will improve outlooks for the industry.
Now that you know what RIM is, learn why it must have a robust structure for defining & managing data in part 2 of this series.
Learn how strategies that extend the bench to bedside philosophy can optimize outcomes for precision medicine trials.
Tina Aswani Omprakash shares her experience of living Crohn’s disease and participating in a clinical trial.
03.27.20 - 2 min - There has been significant momentum to begin repurposing existing drugs to find either prophylactic or acute treatments for COVID-19. These activities could result in further strains on pharmaceutical supply chains when additional capacity needs to come on-line with existing facilities, restarting manufacture, technology transfer to new or alternate facilities and using new or alternate suppliers for components.
03.27.20 - 6 min - Addressing similarities and differences in clinical trial conduct guidances across European Union, FDA, PMDA, NMPA and MHRA
03.26.20 - 3 min - The FDA is moving quickly to implement temporary Guidance to provide flexibility to those pharmacies and compounding centers to produce sanitizing solutions required to meet institutional and consumer demands. However, the current enforcement environment and regulatory actions against compounders may impact their ability to meet this demand, as they are focused on manufacturing critically needed drug products and/or are remediating current Regulatory enforcement activities (DOJ Consent Decree, etc.) that have impacted production and future viability of these firms.
03.25.20 - 6 min - Regulatory strategies, applications, timelines, meetings, inspections and how regulators are working now.
03.24.20 - 5 min - In a direct and timely action to address the acute shortage of diagnostic tests currently available to test for COVID-19 disease, the FDA has issued a new policy that enables both commercial manufacturers and CLIA-certified laboratories to manufacture and distribute validated tests.
